Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 6/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 8/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295114 | 0.86 | ALDH1A1 (0.50) | ALDH1A1CES1CES2FAAHMEN1 | |
| SCHEMBL27629385 | 0.84 | FAAH (0.54) | ALDH1A1CES1CES2FAAHMEN1 | |
| SCHEMBL12363426 | 0.79 | HDAC3 (0.44) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL840286 | 0.79 | — | — | |
| SCHEMBL10170 | 0.77 | HDAC2 (0.52) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL27610327 | 0.75 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL12363412 | 0.75 | ALDH1A1 (0.53) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL12608293 | 0.73 | ALDH1A1 (0.57) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1689290 | 0.73 | HDAC3 (0.48) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL12016626 | 0.73 | HRH3 (0.58) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | claimed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | claimed |
| CN-108912113-A | A kind of application of compound and its alternatively property PI3K inhibitor in the drug of preparation treatment tumour | 王延娇 | 2018-11-30 | — | — | CN | disclosed |
| EP-2702042-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149236-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-01 | — | — | WO | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1954668-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951673-A2 | HETEROCYCLIC CETP INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-6369273-B1 | ARYL ALCOHOLS OR ESTERS FOR ELEVATION OF PYRUVATE DHYDROGENASE | ASTRAZENECA AB (SE) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009488-A1 | Raf Modulators and Methods of Use | BRAF, RAF1, ARAF | HDAC3 1656/4885HDAC1 1107/4885HDAC2 1651/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | HDAC3 1846/4885HDAC1 1821/4885HDAC2 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.